ERYTECH completes enrollment in its Phase III study in Acute Lymphoblastic Leukemia Post author:admERY Post published:September 10, 2013 Post category:Newsroom ERYTECH announces the completion of the enrollment of patients in its pivotal Phase III study in Acute Lymphoblastic Leukemia (ALL). You Might Also Like ERYTECH Announces Results from TRYbeCA-1 Phase 3 Trial of Eryaspase in Patients with Second-line Advanced Pancreatic Cancer October 25, 2021 ERYTECH appoints two new independent board members June 18, 2014 ERYTECH engages in collaborative partnership with EU Horizon 2020 EVIDENCE consortium May 5, 2020
ERYTECH Announces Results from TRYbeCA-1 Phase 3 Trial of Eryaspase in Patients with Second-line Advanced Pancreatic Cancer October 25, 2021